Medicare Drug Price Negotiation: Implementation Challenges and Market Dynamics

This policy brief examines the Inflation Reduction Act's Medicare drug price negotiation provisions 33 months post-enactment. Analysis covers first negotiation cycle results (38-79% price reductions, $6B annual savings), legal landscape, pharmaceutical industry strategic responses, and international pricing comparisons revealing U.S. negotiated prices remain 2-4× higher than single-payer systems. Includes policy recommendations for expanding scope, enabling cost-effectiveness analysis, and implementing reference pricing.